Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Scholar Rock Holding Corporation

Market Cap 5.36B 4.65B 4.28B 4.01B 7.5B 513B 7.66B 51.1B 19.78B 247B 20.1B 19.67B 859B P/E Ratio 2026 *
-14.1x
P/E Ratio 2027 * -17.5x
Enterprise Value 5.05B 4.39B 4.04B 3.79B 7.08B 484B 7.22B 48.22B 18.67B 233B 18.97B 18.56B 811B EV / Sales 2026 *
776x
EV / Sales 2027 * 33.4x
Free-Float
99.25%
Yield 2026 *
-
Yield 2027 * -
1 day+1.36%
1 week-1.41%
Current month-9.35%
1 month-7.57%
3 months+3.50%
6 months-4.57%
Current year+1.45%
1 week 43.23
Extreme 43.23
47.69
1 month 43.23
Extreme 43.23
52.18
Current year 38.75
Extreme 38.75
52.18
1 year 27.07
Extreme 27.07
52.18
3 years 5.93
Extreme 5.93
52.18
5 years 4.32
Extreme 4.325
52.18
10 years 4.32
Extreme 4.325
70
Manager TitleAgeSince
Chief Executive Officer 59 27/04/2025
Director of Finance/CFO 62 27/04/2025
Chief Operating Officer 58 27/04/2025
Director TitleAgeSince
Chairman 59 01/07/2017
Director/Board Member 52 01/08/2014
Director/Board Member 77 01/10/2016
Date Insider Type Main position Quantity % Market Cap.
06-04Free

Director

11,149 0.0097%
06-04Free

Director

11,149 0.0097%
06-04Free

Director

11,149 0.0097%
Change 5-day change 1-year change 3-year change Capi.($)
+1.36%-1.41%+35.38%+538.43% 5.28B
+1.65%+6.42%+53.16%+112.78% 54.82B
+0.03%+0.33%+49.22%+43.94% 43.27B
+3.93%-0.06%-15.10%-18.04% 21.79B
+5.27%-7.82%-1.29%+388.48% 19.92B
+0.53%-8.00%+8.54%-31.70% 15.67B
+0.53%+2.08%+8.89%-39.59% 15.26B
+1.75%+1.92%+29.13%+178.65% 13.22B
+4.56%+4.73%+13.37% - 11.94B
-5.27%-0.43%+87.77%+208.02% 11.58B
Average +1.43%-0.62%+26.91%+153.44% 21.27B
Weighted average by Cap. +1.52%+0.59%+31.53%+109.27%

Financials

2026 *2027 *
Net sales 6.51M 5.65M 5.21M 4.88M 9.12M 624M 9.31M 62.14M 24.06M 301M 24.45M 23.92M 1.05B 149M 130M 120M 112M 209M 14.31B 214M 1.43B 552M 6.9B 561M 549M 23.99B
Net income -410M -356M -328M -307M -574M -39.23B -586M -3.91B -1.51B -18.91B -1.54B -1.5B -65.75B -356M -309M -285M -267M -499M -34.12B -509M -3.4B -1.32B -16.44B -1.34B -1.31B -57.18B
Net Debt -302M -262M -242M -226M -423M -28.92B -432M -2.88B -1.12B -13.94B -1.13B -1.11B -48.48B -356M -309M -284M -267M -498M -34.05B -508M -3.39B -1.31B -16.41B -1.33B -1.31B -57.06B
Logo Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Employees
289
Date Price Change Volume
11/06/26 44.69 $ +1.36% 976,213
10/06/26 44.09 $ -3.27% 1,457,699
09/06/26 45.58 $ +4.06% 994,648
08/06/26 43.80 $ -1.13% 811,977
05/06/26 44.30 $ -2.27% 1,153,268
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
44.69USD
Average target price
59.31USD
Spread / Average Target
+32.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SRRK Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!